- Citations, last 5 years
- 13.8k
- Works, last 5 years
- 2 014
- h-index
- 580
- Scientists listed
- 0
- Grants since 2016
- 630
Grants received
2019–2022 · grant · OCRP
Immunological Approaches for ARID1A-Mutated Ovarian Cancer
Rugang Zhang · The Wistar Institute · funded by Congressionally Directed Medical Research Programs
2019–2024 · research · R50
Applying Molecular and Functional Genomics to Identify Biomarkers for Diagnosing and Treating Cancer
Kiranmai Gumireddy · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Understanding PPARgamma signaling in melanoma brain metastasis
Qing Chen · The Wistar Institute · funded by National Institutes of Health
2019–2022 · grant · OCRP
Development of Novel Small-Molecule Rb Protein Modulator for Ovarian Cancer Immunotherapy
Luis Montaner · The Wistar Institute · funded by Congressionally Directed Medical Research Programs
2019–2021 · fellowship · Career Development Award
DNA-encoded anti-atherogenic therapeutics for reducing LDL and inducing HDL biogenesis
Makan Khoshnejad · The Wistar Institute · funded by American Heart Association
2019–2024 · research · R01
The impact of coding region variants on mutant p53 biology
Maureen E. Murphy · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
The impact of coding region variants on mutant p53 biology
Maureen E. Murphy · The Wistar Institute · funded by National Institutes of Health
2019–2023 · research · R01
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
David B. Weiner · The Wistar Institute · funded by National Institutes of Health
2019–2023 · research · R01
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Alessandro Gardini · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Understanding PPARgamma signaling in melanoma brain metastasis
Qing Chen · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Sialic Acid Modulation of HIV-associated Chronic Inflammaging
Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Sialic Acid Modulation of HIV-associated Chronic Inflammaging
Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health
2019–2021 · research · R21
Host Glycomic Determinants of HIV Persistence in vivo
Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health
2019–2023 · research · R01
Stress Response Functions of ADAR1 Regulated by MAP Kinases
Kazuko Nishikura · The Wistar Institute · funded by National Institutes of Health
2019–2023 · grant · PRCRP
Optimizing Active Immunotherapy of Melanoma Through Metabolic Reprogramming of Melanoma Antigen-Specific CD8+ T Cells Combined with Checkpoint Blockade
Hildegund Ertl · The Wistar Institute · funded by Congressionally Directed Medical Research Programs
2019–2024 · research · R01
Glycomic Modulation of Gut Microbiome During HIV Infection
Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Glycomic Modulation of Gut Microbiome During HIV Infection
Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Glycomic Modulation of Gut Microbiome During HIV Infection
Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health
2019–2022 · award
Role of ARID1A in ovarian carcinogenesis
Alessandro Gardini · The Wistar Institute · funded by American Cancer Society
2019–2023 · research · R01
Stress Response Functions of ADAR1 Regulated by MAP Kinases
Kazuko Nishikura · The Wistar Institute · funded by National Institutes of Health
2019–2030 · research · Global Health
Wistar Institute of Anatomy & Biology - To use these Rubella strain to prepare Master and Working virus seeds which will be used to produce GMP vaccine lots for MR.
The Wistar Institute · funded by Bill and Melinda Gates Foundation
2019–2024 · research · R01
Role of an Integrator-EGR axis in the regulation of myeloid enhancers
Alessandro Gardini · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
David S Metzger · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
David S Metzger · The Wistar Institute · funded by National Institutes of Health
2019–2025 · research · R01
The impact of coding region variants on mutant p53 biology
Maureen E. Murphy · The Wistar Institute · funded by National Institutes of Health
2019–2023 · research · R00
Design of vaccination strategies to elicit broadly neutralizing antibodies against HIV-1
Amelia Escolano · The Wistar Institute · funded by National Institutes of Health
2019–2025 · research · R01
Glycomic Modulation of Gut Microbiome During HIV Infection
Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R50
Applying Molecular and Functional Genomics to Identify Biomarkers for Diagnosing and Treating Cancer
Kiranmai Gumireddy · The Wistar Institute · funded by National Institutes of Health
2019–2023 · research · R01
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
David B. Weiner · The Wistar Institute · funded by National Institutes of Health
2019–2021 · research · R21
Host Glycomic Determinants of HIV Persistence in vivo
Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health
2019–2023 · research · R00
Design of vaccination strategies to elicit broadly neutralizing antibodies against HIV-1
Amelia Escolano · The Wistar Institute · funded by National Institutes of Health
2019–2021 · research · R50
Applying Molecular and Functional Genomics to Identify Biomarkers for Diagnosing and Treating Cancer
Kiranmai Gumireddy · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder
Luis J Montaner · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Effects of mu-opiate receptor engagement on microbial translocation and residual immune activation in HIV-infected, ART suppressed opioid use disorder patents initiating medication-assisted treatment
David S Metzger · The Wistar Institute · funded by National Institutes of Health
2019–2023 · research · R01
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
Rugang Zhang · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Sialic Acid Modulation of HIV-associated Chronic Inflammaging
Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer
Rugang Zhang · The Wistar Institute · funded by National Institutes of Health
2019–2024 · research · R01
Understanding PPARgamma signaling in melanoma brain metastasis
Qing Chen · The Wistar Institute · funded by National Institutes of Health
2019–2020 · grant · LCRP
Regulation of Lung Cancer Dormancy and Recurrence by Stress-Activated Neutrophils
Dmitry Gabrilovich · The Wistar Institute · funded by Congressionally Directed Medical Research Programs
2019–2026 · research · R01
Effects of Mu-opiate receptor engagement on the persistence of HIV-associated activation and viral reservoirs in individuals receiving medication assisted treatment for opioid use disorder
Luis J Montaner · The Wistar Institute · funded by National Institutes of Health